Cat.No. : VNV-034
Storage: -80°C Shipping: Dry ice
| Cat. No. | VNV-034 |
| Description | Wild type west nile viruses (strain: NY 2001-6263) which are inactivated by heat treatment. This product is intended for research use only. |
| Shipping | Dry ice |
| Storage | -80°C |
| Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots. | |
| Mycoplasma | Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination. |
| Purity | Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards. |
| Sterility | The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities. |
| Proviral Identity Confirmation | All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert. |
The clinical range of West Nile Virus (WNV) infection is from influenza-like heat to a more serious neural invasion disease that may cause death. The clinical studies revealed that the astroglial protein S100B is significantly elevated in the blood and CSF of patients with WNV infection, even in the absence of neuro-invasive disease. The study here is to explore the potential role of S100B in the physiological physiology of the WNV infection. Researchers have found that incubation of cultured astroglial cells with UV-inactivated WNV particles caused induction of S100B both at the mRNA and protein levels. S100B of different concentrations stimulates the migration of neutral granulocytes in vitro. In addition, different amounts of S100B inhibit the absorption of glutamic acid by dose -dependent way. These data indicate that inactivated WNV particles are capable of inducing S100B synthesis in astroglia in vitro. Researchers speculate that the S100B released by the active star gel cells may play a variety of role in the pathological physiology of WNV neurological invasion, including inducing neutral cells to be migrated to the destroyed parts of the blood-brain barrier and glutamate neurotoxicity.
Here, the researchers have evaluated the effects of the inactivated WNV particles on the primary star gel cells separated from the cerebral cortex and the cerebellum.The cortical and cerebellar astrocytes showed higher immunoreactivity to S100B than the spinal cord astrocytes. In addition, the S100B protein was found to be associated with vimentin filaments in these primary astrocytic cultures (Figure 1a). Researchers noticed up-regulation of S100B in the cerebellar and cortical astroglial cultures treated with inactivated WNV particles (Figure 1b and c). The up-regulation of S100B was not only at the protein level but also at the RNA level, as confirmed by the mRNA expression analysis using Real-Time PCR (Figure 1d). S100B mRNA levels were markedly higher both at 24 and 48 h in the cultures treated with inactivated WNV particles as compared to mock media (Figure 1d). The ELISA (Figure 1e) and Western blot (Figure 1f) analysis revealed a marked increase in S100B, both in the conditioned media and cell lysates, respectively after exposure to UV inactivated WNV particles in comparison to the mock treated.
Figure 1. Treatment of primary glial cultures with inactivated WNV particles. (Kuwar R B, et al., 2015)
A: West Nile virus (WNV) is the leading cause of mosquito-borne disease in the continental United States. It is most commonly spread to people by the bite of an infected mosquito. About 1 in 5 people who are infected develop a fever and other symptoms.
A: Lineage 1 is composed of WNV strains from different geographic regions, and it is subdivided into at least 3 clades. Clade A contains strains from Europe, Africa, the Middle East, and America; clade B represents the Australian (Kunjin) strains; and clade C contains Indian WNV isolates.
A: Wild-type West Nile Virus refers to the naturally occurring strain of the virus that is found in nature without any modifications or genetic manipulations.
A: Yes, the Wild-Type West Nile Virus products we offer are safe to handle within a laboratory setting when proper biosafety measures are followed. These products are intended exclusively for research purposes and should only be utilized by trained personnel who adhere to appropriate safety guidelines, biosafety level requirements, and institutional regulations.
A: West Nile virus (WNV) is a single-stranded RNA virus that causes West Nile fever. It is a member of the genus Flavivirus in the family Flaviviridae.
A: West Nile virus is a positive-sense single-stranded RNA virus. Its genome is approximately 11,000 nucleotides long and is flanked by 5' and 3' noncoding stem-loop structures.
A: Like most other flaviviruses, West Nile virus is an enveloped virus with icosahedral symmetry. Electron microscopy studies show that 45-50 nm virions are covered with a relatively smooth protein coat.
A: Most people infected with West Nile virus do not experience any symptoms, but approximately 20% may develop a fever, headache, body aches, fatigue, skin rash, or swollen lymph glands.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Wild-Type West Nile Virus I purchased from Creative Biogene had high titers and yielded good results in immunoassay studies.
It is a reliable product for immunoassay research and development because it is produced by cell line culture and has proven activity.
The virus is potent and has provided consistent and reproducible outcomes in my studies.
I am extremely satisfied with this product's performance. The product was easy to work with and delivered robust results in my experiments.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
